No results found
An epigenome editing toolkit to dissect the mechanisms of gene regulation
A study from the Hackett group at EMBL Rome led to the development of an epigenetic editing system that allows to precisely program chromatin modifications at any specific position in the genome, to understand their causal role in transcription regulation.
SCIENCE & TECHNOLOGY2024
science-technology
EMBL and ZEISS enter long-term strategic partnership
Through the collaborative framework agreement, EMBL and ZEISS aim to accelerate the development of imaging technology to advance life science research.
CONNECTIONSLAB MATTERS2023
connectionslab-matters
David Hulcoop appointed as Open Targets Director
Coming from a pharmaceutical industry background, David Hulcoop is set to take over as Executive Director of the public-private partnership Open Targets.
EMBL ANNOUNCEMENTS2023
announcementsembl-announcements
IMAGINE-ing next-generation technology to help biologists
EMBL researchers and collaborators have begun an impactful innovation-development journey, thanks to a European Commission ‘IMAGINE’ grant.
CONNECTIONSLAB MATTERS2023
connectionslab-matters
Vizgen joins EMBL science-industry programme
Vizgen, the life science company dedicated to improving human health by visualising single-cell spatial genomics information, has joined EMBL’s Corporate Partnership Programme.
CONNECTIONSLAB MATTERS2023
connectionslab-matters
New EU-funded Project: Fragment-Screen
EMBL is one of the partners of this project that aims to accelerate drug discovery and development, bringing in expertise from EMBL Grenoble and EMBL-EBI.
LAB MATTERSSCIENCE & TECHNOLOGY2023
lab-mattersscience-technology